Firsocostat - Gilead Sciences
Alternative Names: GS-0976; NDI 010976Latest Information Update: 03 Jan 2023
Price :
$50 *
At a glance
- Originator Nimbus Therapeutics
- Developer Gilead Sciences; Nimbus Therapeutics
- Class Anti-inflammatories; Hepatoprotectants; Propionic acids; Pyridines; Small molecules
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 04 Nov 2022 Pharmacodynamics data from a phase II ATLAS trial in Nonalcoholic steatohepatitis presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Germany (PO, Tablet)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Romania (PO, Tablet)